What is Lynparza
OlaparibThe Generic name of this drug
Treatment SummaryOlaparib is a medication used to treat certain types of cancer. It is a PARP inhibitor, meaning it blocks enzymes in the body that help with normal cell functioning, such as DNA transcription and repair. Olaparib is available as a tablet under the brand name Lynparza and is used to treat recurrent ovarian, fallopian tube, or primary peritoneal cancer, as well as certain types of breast cancer. It has been approved for use both as monotherapy and after chemotherapy. Studies have shown that it can reduce the risk of disease progression or death by up to 70%, making it an important frontline treatment option for
Lynparzais the brand name
Lynparza Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Lynparza
Olaparib
2014
3
Approved as Treatment by the FDA
Olaparib, commonly known as Lynparza, is approved by the FDA for 7 uses like maintenance therapy and Pharmacotherapy .maintenance therapy
Used to treat maintenance therapy in combination with Bevacizumab
Pharmacotherapy
Used to treat previous first-line chemotherapy in combination with Bevacizumab
Pharmacotherapy
Used to treat responsive to platinum-based chemotherapy in combination with Bevacizumab
Advance Directives
Used to treat Advanced Fallopian Tube Carcinoma in combination with Bevacizumab
Homologous Recombination Deficiency (HRD)
Used to treat Homologous Recombination Deficiency (HRD) in combination with Bevacizumab
Advanced Epithelial Ovarian Cancer
Used to treat Advanced Epithelial Ovarian Cancer in combination with Bevacizumab
Advanced Primary Peritoneal Carcinoma
Used to treat Advanced Primary Peritoneal Carcinoma in combination with Bevacizumab
Effectiveness
How Lynparza Affects PatientsOlaparib is a medication used to treat cancer. It works by inhibiting the growth of certain types of cancer cells, both on its own and when combined with chemotherapy and/or radiation. Olaparib can also make chemotherapy and radiation more effective by blocking the repair of damaged DNA, which makes cancer cells more vulnerable to treatment.
How Lynparza works in the bodyOlaparib is a medicine that targets poly(ADP-ribose) polymerases (PARPs). PARPs are enzymes that help repair damaged DNA. Olaparib specifically targets PARP1 and PARP2 and blocks them from doing their job, leading to the accumulation of unrepaired DNA damage. This unrepaired DNA damage can cause cancer cells with BRCA1/2 mutations to become unstable and die. Olaparib has been shown to be effective in _in vitro_ studies, leading to cancer cell death through the inhibition of PARP enzymatic activity and increased formation of PARP-
When to interrupt dosage
The measure of Lynparza is contingent upon the diagnosed affliction, for example, Pharmacotherapy, Malignant Peritoneal Neoplasm and Ovarian Cancer. The dose fluctuates as per the method of delivery (e.g. Tablet - Oral or Oral) stated in the table below.Condition
Dosage
Administration
Hallucinations, Somatic
150.0 mg, 100.0 mg, , 50.0 mg
Tablet - Oral, Oral, Tablet, film coated - Oral, Capsule, Tablet, film coated, Tablet, , Capsule - Oral
Pharmacotherapy
150.0 mg, 100.0 mg, , 50.0 mg
Tablet - Oral, Oral, Tablet, film coated - Oral, Capsule, Tablet, film coated, Tablet, , Capsule - Oral
Malignant Peritoneal Neoplasm
150.0 mg, 100.0 mg, , 50.0 mg
Tablet - Oral, Oral, Tablet, film coated - Oral, Capsule, Tablet, film coated, Tablet, , Capsule - Oral
Epithelial Ovarian Cancer
150.0 mg, 100.0 mg, , 50.0 mg
Tablet - Oral, Oral, Tablet, film coated - Oral, Capsule, Tablet, film coated, Tablet, , Capsule - Oral
Ovarian Cancer
150.0 mg, 100.0 mg, , 50.0 mg
Tablet - Oral, Oral, Tablet, film coated - Oral, Capsule, Tablet, film coated, Tablet, , Capsule - Oral
previous chemotherapy
150.0 mg, 100.0 mg, , 50.0 mg
Tablet - Oral, Oral, Tablet, film coated - Oral, Capsule, Tablet, film coated, Tablet, , Capsule - Oral
Pharmacotherapy
150.0 mg, 100.0 mg, , 50.0 mg
Tablet - Oral, Oral, Tablet, film coated - Oral, Capsule, Tablet, film coated, Tablet, , Capsule - Oral
Malignant neoplasm of ovary
150.0 mg, 100.0 mg, , 50.0 mg
Tablet - Oral, Oral, Tablet, film coated - Oral, Capsule, Tablet, film coated, Tablet, , Capsule - Oral
advanced deleterious germline or somatic BRCA-mutated peritoneal cancer
150.0 mg, 100.0 mg, , 50.0 mg
Tablet - Oral, Oral, Tablet, film coated - Oral, Capsule, Tablet, film coated, Tablet, , Capsule - Oral
Metastatic Breast Cancer
150.0 mg, 100.0 mg, , 50.0 mg
Tablet - Oral, Oral, Tablet, film coated - Oral, Capsule, Tablet, film coated, Tablet, , Capsule - Oral
Primary Peritoneal Cancer
150.0 mg, 100.0 mg, , 50.0 mg
Tablet - Oral, Oral, Tablet, film coated - Oral, Capsule, Tablet, film coated, Tablet, , Capsule - Oral
Advance Directives
150.0 mg, 100.0 mg, , 50.0 mg
Tablet - Oral, Oral, Tablet, film coated - Oral, Capsule, Tablet, film coated, Tablet, , Capsule - Oral
Warnings
There are 20 known major drug interactions with Lynparza.Common Lynparza Drug Interactions
Drug Name
Risk Level
Description
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Olaparib is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Olaparib.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Olaparib.
Acteoside
Major
The risk or severity of adverse effects can be increased when Olaparib is combined with Acteoside.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Olaparib.
Lynparza Toxicity & Overdose RiskThe toxic dose of olaparib in rats is 240-300 mg/kg. There is not a lot of information available regarding an overdose of olaparib.
Lynparza Novel Uses: Which Conditions Have a Clinical Trial Featuring Lynparza?
At present, 211 active studies are analyzing the potential of Lynparza to address Ovarian Cancer, Hallucinations, Somatic and Metastatic Breast Cancer.Condition
Clinical Trials
Trial Phases
Hallucinations, Somatic
0 Actively Recruiting
Ovarian Cancer
68 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1
Metastatic Breast Cancer
82 Actively Recruiting
Phase 2, Not Applicable, Phase 3, Phase 1, Phase 4
Primary Peritoneal Cancer
26 Actively Recruiting
Phase 2, Phase 1, Phase 3, Early Phase 1
Malignant neoplasm of ovary
0 Actively Recruiting
Advance Directives
0 Actively Recruiting
Malignant Peritoneal Neoplasm
23 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3
previous chemotherapy
0 Actively Recruiting
Epithelial Ovarian Cancer
29 Actively Recruiting
Phase 2, Phase 1, Phase 3, Not Applicable
advanced deleterious germline or somatic BRCA-mutated peritoneal cancer
0 Actively Recruiting
Pharmacotherapy
0 Actively Recruiting
Pharmacotherapy
0 Actively Recruiting
Lynparza Reviews: What are patients saying about Lynparza?
5Patient Review
12/8/2016 My hemoglobin was low for the first few months, but I wasn't as tired. Now my hemoglobin is 12.5 and my CA 125 is 12.2. I just had my dose reduced yesterday because of muscle and joint pain, but these are side effects that I can live with.
5Patient Review
7/13/2016 Lynparza was my last-ditch effort after first-line IV/IP chemo failed to give me remission. I'm so grateful that it only took 10 weeks on this medication to achieve what the other couldn't. I originally had to take 8 pills, twice a day; however, due to severe anemia, I had to halve my dose. Thank goodness, everything's been good since then!
5Patient Review
6/21/2016 Though this treatment is tough - having to forego food for an hour around each dose, and experiencing some pain as a result of the medication - it has been worth it. My cancer markers have dropped significantly in just three months, and I'm feeling better than I have in years.
4.7Patient Review
5/23/2016 I only have one issue with this treatment- I get a sun exposure rash on my arms when it gets warm outside.
3.7Patient Review
1/17/2020 At first, I experienced a lot of side effects that nearly made me give up on this treatment. However, after a few weeks I was able to adjust. I mostly felt physically exhausted and depressed. But it's been worth it because my tumors are gone and I hope to continue this treatment as long as it doesn't prevent me from enjoying life.
3Patient Review
11/14/2021 My daughter was in remission for 18 months, but unfortunately developed AML from the treatment and passed away this month. Please be vigilant about monitoring your blood counts if you're on this medication; frequent transfusions may be a sign that your body can't handle the drug.
1.3Patient Review
2/10/2022 My aunt was suggested this medication by her doctor after chemotherapy in an effort to improve her condition; however, it made her worse very rapidly and she passed away soon after.
Patient Q&A Section about lynparza
Is Lynparza a chemotherapy?
"A targeted therapy is a cancer treatment that targets the changes in cancer cells that help them grow, divide, and spread.
Lynparza is the trade name for olaparib, a chemotherapy drug. In some cases, health care professionals may use the generic name olaparib when referring to the trade drug name Lynparza. Lynparza is a targeted therapy, meaning it targets changes in cancer cells that help them grow, divide, and spread." - Anonymous Online Contributor
Unverified Answer
What cancers does Lynparza treat?
"LYNPARZA is used to treat adults with advanced [ovarian cancer](https://www.withpower.com/clinical-trials/ovarian-cancer), fallopian tube cancer, or primary peritoneal cancer who have a certain type of mutated (inherited or acquired) BRCA gene." - Anonymous Online Contributor
Unverified Answer
Does Lynparza shrink tumors?
"Lynparza may be prescribed as an active treatment to decrease cancer growth or maintenance treatment to stop cancer from recurring by health professionals." - Anonymous Online Contributor
Unverified Answer
Does Lynparza cure cancer?
"While the approval of Lynparza is great news for treating cancers in BRCA mutation carriers, much work remains. Lynparza has been approved for use in ovarian cancer patients who received three prior chemotherapies, making it a “fourth line” drug." - Anonymous Online Contributor
Unverified Answer
How long do you stay on Lynparza?
"On average, patients taking Lynparza stayed on the medication for 24.6 months, while those taking placebo only stayed on the medication for 13.9 months." - Anonymous Online Contributor
Unverified Answer